Stocks Health care TELA
NASDAQ · Health careTELA Bio, Inc. (TELA)
TELA Bio, Inc. brought in $79.9M of revenue over the twelve months to June 30, 2026, up 6.1% from a year earlier. It posted a net loss of $41.2M. In fiscal 2025 capital spending exceeded operating cash flow by $28.7M. At June 30, 2026 it held $30.4M in cash against $56.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What TELA Bio, Inc. does
TELA Bio, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker TELA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $80.3M | -$38.8M | -$0.83 | -$28.7M |
| 2024 | $69.3M | -$37.8M | -$1.33 | -$42.6M |
| 2023 | $58.5M | -$46.7M | -$2.04 | -$41.5M |
| 2022 | $41.4M | -$44.3M | -$2.72 | -$41.6M |
| 2021 | $29.5M | -$33.3M | -$2.30 | -$31.1M |
| 2020 | $18.2M | -$28.8M | -$2.23 | -$24.6M |
Full financial statements: income, balance sheet and cash flow
Where TELA ranks in Health care
Latest SEC filings
What TELA Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 14, 2026Proxy statement DEF 14A
- September 4, 2026Preliminary proxy statement PRE 14A
- August 31, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 4.5% to $19.3M versus the same quarter last year; diluted EPS -$0.20 versus -$0.22.
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running TELA Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $186K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Capper Joseph HDirector | Bought | 25,000 | $30.5K |
| September 16, 2026 | Capper Joseph HDirector | Bought | 50,000 | $58.3K |
| September 15, 2026 | Capper Joseph HDirector | Bought | 50,000 | $52.9K |
| September 14, 2026 | Capper Joseph HDirector | Bought | 25,000 | $25.5K |
| August 17, 2026 | Getz Heather CChief Executive Officer, Director | Bought | 12,500 | $8.3K |
| August 14, 2026 | Getz Heather CChief Executive Officer, Director | Bought | 15,000 | $10.5K |
| August 3, 2026 | Getz Heather CChief Executive Officer, Director | Received as pay | 500,000 | - |
| July 15, 2026 | Capper Joseph HDirector | Received as pay | 6,227 | $4.9K |
| July 15, 2026 | Plovanic William J.Director | Received as pay | 20,930 | $16.4K |
| June 9, 2026 | Capper Joseph HDirector | Received as pay | 11,925 | - |
| June 9, 2026 | Capper Joseph HDirector | Received as pay | 11,675 | - |
| June 9, 2026 | Rocchio Betty JoDirector | Received as pay | 11,675 | - |
Who owns TELA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| EW Healthcare Partners Fund 2-GP, L.P.13D, may seek influence with 3 related filers | 17.23% | June 9, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 12.94% | August 14, 2026 |
| EW Healthcare Partners Fund 2-UGP, LLC13G, passive with 3 related filers | 10.44% | October 28, 2024 |
| Laurence W. Lytton13G, passive | 9.9% | November 14, 2024 |
| North Run Capital, LP13G, passive with 6 related filers | 9.3% | May 30, 2025 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 6% | February 13, 2025 |
| Lytton, Laurence W.13G, passive | 5.5% | May 15, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 780,457 shares in total, about $983.4K at the last price.
| Holder | Shares |
|---|---|
| Getz Heather CChief Executive Officer, Director | 532,500 |
| Capper Joseph HDirector | 179,827 |
| Plovanic William J.Director | 44,530 |
| Rocchio Betty JoDirector | 23,600 |
Questions about TELA
What does TELA Bio, Inc. do?
TELA Bio, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker TELA.
Is TELA Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $41.2M on revenue of $79.9M.
How much revenue does TELA Bio, Inc. make?
Over the twelve months to June 30, 2026 TELA Bio, Inc. reported revenue of $79.9M. That is 6.1% more than a year earlier.
When did TELA Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from September 18, 2026.
Similar companies
Compare TELA with
Follow TELA
Get an email when TELA Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TELA: get an email when it filesWhere the numbers come from
Financial figures are the values TELA Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.